Enables to analyze Korean pharma/biotech stocks using clinical trial data from ClinicalTrials.gov and market data from Naver Finance, providing 100-point scoring, decision labels, and technical indicators.
Enables comprehensive medical research by querying and analyzing data across ClinicalTrials.gov, PubMed, and FDA databases with AI-enhanced cross-database insights, risk assessments, and competitive intelligence.
Enables scientific due diligence by grading claims against public literature, clinical trials, and filings, with explicit citations and optional attestation.
Enables aggregated investment research by combining data from Yahoo/SEC EDGAR, Finnhub, and GDELT with analysis modules for price momentum, news signals, and estimate revisions.
Provides read-only tools to retrieve source-linked catalyst evidence dossiers for public-company tickers, including deterministic catalyst scores and paged source records.